🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing around the world, with figures suggesting in excess of 82 million new cases each year. Particularly high rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in the same week. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This authorization signifies a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Data and Global Access

Based on data detailed in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This puts it on an comparable level with the typical regimen, which involves a dual-drug approach. The study involved hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have expressed positive views. The availability of a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is deemed crucial to alleviate the strain of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.